Study guide

Renal Impairment, CI-AKI Risk & Metformin Management

NMTCB CT

Track your progress as you read

Finished sections get a check mark.

1 CT System Hardware & X-Ray Generation

X-Ray Tube Design and Focal Spots Tube Heat Loading, Bearings and Cooling Beam Filtration and Collimation Scanner Generations and Source/Detector Geometry Detector Technology & Data Acquisition Systems (DAS)

2 Gantry Mechanics & Ancillary Systems

Gantry Architecture, Clearance and Centering Slip Rings, Couch Motion and Load Safety Power Injector Hardware and Safety DICOM, Worklists and Image Archiving

3 Data Acquisition & Scanning Geometries

Axial vs. Helical Scanning & Pitch Mechanics Localizer/Scout Scans & Isocenter Alignment Beam Geometry, Slice Collimation & Data Sampling

4 Mathematical Reconstruction & Image Processing

Projection Data, Image Matrices and Voxel Sampling Filtered Back Projection and Reconstruction Kernels Iterative Reconstruction & AI-Powered Algorithms Hounsfield Unit Scale, Linear Attenuation & Windowing (WW/WL)

5 3D Visualization & Advanced Post-Processing

Multiplanar Reformation (MPR) & Curved Planar Reformation (CPR) Volume Rendering, Maximum/Minimum Intensity Projections & Virtual Endoscopy

6 Image Quality & Performance Metrics

Spatial Resolution, Modulation Transfer Function & Matrix Parameters MTF and Spatial-Resolution Testing Contrast Resolution, Quantum Noise & Temporal Resolution Interdependence of Image Quality Parameters & Radiation Dose

7 CT Artifacts Identification & Correction

Physics-Based Artifacts: Beam Hardening, Cupping & Partial Volume Averaging Equipment & Patient Artifacts: Ring, Motion, Metal & Windmill Effects

8 Quality Assurance & Routine Testing

Daily Quality Control: Water Calibration, Noise & Field Uniformity Periodic Quality Assurance: ACR Phantom Testing & Geometry Verification

9 Patient Communication, Screening & Preparation

Patient Identification, Clinical Screening & Pregnancy Protocols Informed Consent, Pre-Scan Fasting & Anxiety Management Patient Monitoring, Vital Signs Assessment & ECG Gating Setup

10 Infection Control & Medical Emergency Response

Infection Control, Aseptic Technique & Scanner Disinfection Medical Emergencies in the CT Suite: Vasovagal Reactions, Seizures & Code Protocols

11 Contrast Media Chemistry & Administration

Iodinated Contrast Properties: Osmolality, Viscosity & Molecular Structure Contrast Volume, Flow, Duration and Iodine Delivery Intravenous Access, Catheter Gauges & Power Injection Protocols Bolus Tracking, Test Bolus & Contrast Transit Dynamics

12 Non-Vascular Contrast & Adverse Reactions

Oral, Rectal and Enteral Contrast Intrathecal, Intra-articular and Cavitary Contrast Renal Impairment, CI-AKI Risk & Metformin Management Contrast Reactions: Categorization, Prophylaxis & Emergency Treatment

13 Neuroimaging & Head/Neck CT Protocols

Routine Brain and Trauma CT Technique Stroke, Hemorrhage and Targeted Skull-Base CT Facial Bones, Orbits & High-Resolution Temporal Bones Soft Tissue Neck & Paranasal Sinuses Protocols

14 Thoracic & Cardiovascular CT Protocols

Routine Chest CT: Pulmonary Parenchyma & Mediastinal Anatomy High-Resolution CT (HRCT) for Diffuse Interstitial Lung Disease Pulmonary Embolism & Cardiac CT Protocols

15 Abdominal & Pelvic CT Protocols

Multiphase Liver, Pancreas & Renal CT Protocols Gastrointestinal CT: Enterography, Colonography & Acute Abdomen Pelvic Cross-Sectional Anatomy & Gynecologic/Urologic Pathology

16 Musculoskeletal, Vascular & Interventional CT

Cervical, Thoracic and Lumbosacral Spine CT Extremity, Joint and Orthopedic Hardware CT CT Angiography (CTA): Carotid, Aortic & Peripheral Runoff Protocols CT-Guided Interventions: Biopsy, Abscess Drainage & Procedural Safety

17 Hybrid PET/CT and SPECT/CT Procedures

PET/CT Anatomy, Physiology and Attenuation Correction SPECT/CT Anatomy, Physiology and Attenuation Correction

18 Radiation Biology & Dose Descriptors

Radiation Physics, Cellular Interactions & Biological Risk Models Tissue Reactions, Stochastic Risk and Justification CTDI Measurement and Phantom References CTDI Weighting, Pitch and DLP Calculations Size-Specific Dose Estimates Effective-Dose Estimates and Diagnostic Reference Levels

19 Radiation Protection & Dose Optimization

Technical Dose Reduction: Tube Current Modulation & Pediatric ALARA Pediatric, Body-Habitus and Pregnancy Optimization Personnel Protection, Distance and Shielding Jurisdiction, Dose Limits and Personnel Monitoring

Renal Impairment, CI-AKI Risk & Metformin Management

Key Takeaways Explain This Topic AI

CA-AKI describes temporal association and does not prove contrast causation.

Stable eGFR at least 30 without AKI does not require routine metformin interruption under ACR guidance.

Renal prophylaxis is individualized for AKI and severe impairment.

Last updated: October 2026

Association and causation

An acute kidney injury after contrast is contrast-associated AKI (CA-AKI): the timing alone does not establish that contrast caused the injury. Contrast-induced AKI (CI-AKI) describes the smaller causal subset. Hospitalized patients may have dehydration, sepsis, hypotension, obstruction, medications, or surgery that explain worsening renal function independently of contrast. Calling every creatinine rise “contrast nephropathy” can lead to withholding a useful examination while overlooking the actual cause.

The technologist identifies risk factors, checks the available laboratory information, and escalates concerns to the radiologist or prescribing team. The decision compares the diagnostic benefit of enhancement with renal and other risks. An urgent examination can be appropriate even in severe renal impairment; there is no universal creatinine concentration above which iodinated contrast must never be given.

ACR metformin categories

  • Renal/procedural condition General ACR approach
  • No AKI; stable eGFR at least 30; routine IV iodine No routine interruption required solely for contrast
  • AKI or eGFR below 30 Hold at/before, withhold 48 hours and reassess before resuming

Arterial catheter study with renal embolic risk Apply Category II assessment; not every IV CTA is this procedure

Interpreting eGFR and AKI

Estimated glomerular filtration rate is a more useful screening measure than an isolated serum creatinine in a patient with stable renal function. It depends on the estimating equation and patient characteristics. Serum creatinine can lag behind an acute change in function, so a seemingly reassuring eGFR does not exclude AKI. Trends, recent clinical events, urine output, and the clinical history matter.

Screen for known kidney disease, prior renal surgery, dialysis, previous AKI, and other risks specified by local policy. Determine whether a laboratory result is recent enough for the patient's situation. An inpatient whose condition has changed may require a new assessment even when an older outpatient result was acceptable. Do not infer a fixed laboratory-validity interval from an exam question unless the policy is stated.

Stable patients with eGFR at least 30 mL/min/1.73 m² generally do not need prophylactic volume expansion solely for IV iodinated contrast. ACR recommends considering prophylaxis for AKI or severe chronic kidney disease with eGFR below 30, while weighing heart failure and other risks of volume expansion. For eGFR 30–44, prophylaxis may be considered individually when additional high-risk circumstances exist; it is not mandatory for every patient in that range.

Prevention and follow-up

Isotonic IV saline is the usual preferred volume-expansion method when prophylaxis is indicated. Timing, volume, and infusion rate are individualized by the treating clinician. A patient with pulmonary edema or decompensated heart failure can be harmed by a routine fluid-loading schedule. Oral hydration alone should not be presented as an established substitute for prophylaxis in AKI or severe chronic kidney disease.

Sodium bicarbonate has not demonstrated an advantage over saline and is not preferred by ACR because of preparation requirements. N-acetylcysteine is not recommended for IV-contrast renal prophylaxis. Mannitol and furosemide are not renal-protection treatments for this purpose. This does not mean a diuretic prescribed for an independent clinical indication must automatically be stopped by the technologist.

Use a diagnostically adequate contrast dose chosen by the radiologist. Reducing the dose until the study becomes nondiagnostic creates risk and may lead to another exposure. Record the agent, concentration, volume, route, and any adverse event. Follow-up testing is selected for the clinical situation rather than ordered automatically for every contrast recipient.

Dialysis patients

An anuric patient with end-stage renal disease does not have functioning renal tissue to injure in the usual way, but volume and osmotic loads still require consideration. A dialysis patient who retains meaningful urine output may have residual renal function worth protecting. ACR does not recommend initiating dialysis or changing its schedule solely because IV iodinated contrast was administered. Coordinate care with the responsible team rather than promising immediate dialysis will prevent an injury.

Metformin: the ACR categories

Metformin itself is not a nephrotoxic drug and does not increase the risk of CA-AKI. The concern is accumulation of metformin if significant renal dysfunction develops, which can contribute to lactic acidosis. Renal function and the procedure determine the precautions; taking metformin alone is not a contrast contraindication.

Under ACR guidance, a patient with no AKI and eGFR at least 30 may continue metformin for IV iodinated contrast. There is no obligatory post-contrast renal test solely because that patient takes metformin. In AKI, eGFR below 30, or an arterial catheter procedure that could send emboli to the renal arteries, metformin is held at or before the procedure and for 48 hours afterward. The clinician reassesses renal function before resuming it.

An IV CT angiogram is different from an intra-arterial catheter examination. Do not apply the embolic-risk rule to every examination whose name contains “angiography.” FDA labeling and some institutional policies are more restrictive than ACR; follow the authorized local policy and clarify differences with the clinician. The guide's categories identify the ACR recommendation rather than overruling an order.

Worked screening decisions

A stable patient with eGFR 36, no AKI, and metformin use does not automatically enter ACR Category II. Under ACR IV-contrast guidance, metformin can continue, and hydration is considered only if the broader risk assessment supports it. A patient with eGFR 26 or an active AKI needs clinician review, consideration of prophylaxis, and the Category II metformin precautions. The difference is the patient's renal condition, not the mere presence of diabetes on a checklist.

Reference: ACR Manual on Contrast Media .